| P50 | author | France Mentré | Q87317141 |
| | Jérôme Stirnemann | Q89761806 |
| | Olivier Fain | Q114301300 |
| | Nadia Belmatoug | Q117223230 |
| P2093 | author name string | Bruno Fantin | |
| | Corine Vincent | |
| P2860 | cites work | Biomarkers for lysosomal storage disorders: identification and application as exemplified by chitotriosidase in Gaucher disease | Q33323654 |
| | METABOLISM OF GLUCOCEREBROSIDES. II. EVIDENCE OF AN ENZYMATIC DEFICIENCY IN GAUCHER'S DISEASE. | Q33355882 |
| | Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients | Q33356246 |
| | Type 2 Gaucher disease: 15 new cases and review of the literature | Q33370289 |
| | Tartrate-resistant acid phosphatase staining of monocytes in Gaucher disease | Q33459713 |
| | Molecular and cell biology of acid beta-glucosidase and prosaposin | Q34070568 |
| | Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease | Q34133643 |
| | Serum ferritin concentration in Gaucher's disease | Q34992481 |
| | Recent clinical progress in Gaucher disease | Q36191776 |
| | Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study | Q36737076 |
| | Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. | Q37221766 |
| | Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis | Q37413920 |
| | Elevation of Serum Angiotensin-Converting Enzyme in Gaucher's Disease | Q39991377 |
| | Plasma and metabolic abnormalities in Gaucher's disease. | Q41719188 |
| | Neuronopathic forms of Gaucher's disease | Q41719191 |
| | Immunochemical characterization of two activator proteins stimulating enzymic sphingomyelin degradation in vitro. Absence of one of them in a human Gaucher disease variant | Q42509294 |
| | Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002. | Q43687450 |
| | Correlation of surrogate markers of Gaucher disease. Implications for long-term follow up of enzyme replacement therapy | Q47586472 |
| | A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. | Q51501369 |
| | The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. | Q53241550 |
| | Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease in 30 adult patients. | Q53968058 |
| | Evaluation of three biochemical markers in the monitoring of Gaucher disease | Q59401760 |
| | Gaucher disease | Q68144895 |
| | Age dependency of serum acid phosphatase in controls and Gaucher patients | Q70671847 |
| | beta-Glucosidase assays in the diagnosis of Gaucher's disease | Q71600806 |
| | Elevation of serum acid phosphatase in Gaucher's disease | Q73969954 |
| | Serum chitotriosidase activity in Gaucher patients on enzyme replacement therapy (ERT) | Q77166181 |
| | Gaucher disease | Q77373645 |
| | Disease system analysis: basic disease progression models in degenerative disease | Q80390429 |
| | Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients | Q80828454 |
| | Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease | Q81123039 |
| P433 | issue | 4 | |
| P921 | main subject | Gaucher's disease | Q861645 |
| P304 | page(s) | R156 | |
| P577 | publication date | 2010-08-09 | |
| P1433 | published in | Arthritis Research and Therapy | Q15757229 |
| P1476 | title | Bone events and evolution of biologic markers in Gaucher disease before and during treatment | |
| P478 | volume | 12 | |